These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29697184)

  • 21. Second allogeneic transplantation using umbilical cord blood for a patient with relapsed ALK+ anaplastic large cell lymphoma after allogeneic bone marrow transplantation in the era of ALK inhibitors: A case report.
    Saito S; Tashiro H; Sumiyoshi R; Matsuo T; Yamamoto T; Matsumoto K; Ooi J; Shirafuji N
    Medicine (Baltimore); 2021 Apr; 100(15):e25576. PubMed ID: 33847688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.
    Pearson JD; Zhang J; Wu Z; Thew KD; Rowe KJ; Bacani JT; Ingham RJ
    Mol Cancer; 2014 Aug; 13():199. PubMed ID: 25168906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
    Boi M; Zucca E; Inghirami G; Bertoni F
    Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The γ-secretase inhibitor GSI-I interacts synergistically with the proteasome inhibitor bortezomib to induce ALK+ anaplastic large cell lymphoma cell apoptosis.
    Dang Q; Chen L; Xu M; You X; Zhou H; Zhang Y; Shi W
    Cell Signal; 2019 Jul; 59():76-84. PubMed ID: 30878517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA/SFGM-TC study.
    Morel A; Brière J; Lamant L; Loschi M; Haioun C; Delarue R; Tournilhac O; Bachy E; Sonet A; Amorim S; Laurent C; Gaulard P; Tilly H; Sibon D
    Eur J Cancer; 2017 Sep; 83():146-153. PubMed ID: 28735072
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
    Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
    PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the Treatment of Anaplastic Large Cell Lymphoma.
    Vu K; Ai W
    Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
    Uchihara Y; Ueda F; Tago K; Nakazawa Y; Ohe T; Mashino T; Yokota S; Kasahara T; Tamura H; Funakoshi-Tago M
    PLoS One; 2017; 12(8):e0183003. PubMed ID: 28806414
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intrinsic apoptotic pathway in anaplastic large cell lymphoma.
    Oyarzo MP; Drakos E; Atwell C; Amin HM; Medeiros LJ; Rassidakis GZ
    Hum Pathol; 2006 Jul; 37(7):874-82. PubMed ID: 16784988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
    Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
    [No Abstract]   [Full Text] [Related]  

  • 37. Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
    Chen MT; Fu XH; Huang H; Wang Z; Fang XJ; Yao YY; Ren QG; Chen ZG; Lin TY
    Leuk Lymphoma; 2021 Mar; 62(3):571-580. PubMed ID: 33155495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents.
    Rigaud C; Knörr F; Brugières L; Woessmann W
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101444. PubMed ID: 36907641
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
    Minich SS
    Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.